-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Ferring Pharmaceuticals and its subsidiary Rebiotix announced the results of two key retrospective analyses on RBX2660 at the American Academy of Gastroenterology (ACG) 2021 meeting, involving the use of RBX2660 in the treatment of recurrent Clostridium difficile infection (rCDI).
) And inflammatory bowel disease (IBD)
.
Among them, after treatment with RBX2660, 82.
8% of 94 patients with common comorbidities with recurrent CDI (rCDI) had no recurrence of CDI at eight weeks after administration, and received one dose (83.
3%) and two doses (82.
5%).
) There was no difference between the treated patients
.
In the cohort that experienced remission after the first dose, 88.
In addition, the researchers conducted real-world comparisons of the outcome and medical resource consumption of patients 65 years of age or older who had at least one episode of CDI with or without IBD
.
The analysis is based on Medicare data analyzed from 2009 to 2017, including a total of 497,489 CDI patients, of which 36,059 were diagnosed with IBD
Although the hospitalization rate in all study groups is high, patients with CDI and IBD occupy more medical resources, including longer hospital stays and a higher rate of 30-day readmissions
.
Among the dead patients, the monthly expenses of those with CDI and UC were significantly higher than those with CD
Clostridium difficile is a bacterium that causes diarrhea and colitis
.
It is estimated that every year in the United States alone, as many as 500,000 people get sick and may cause serious complications, including hospitalization, surgery, and death
RBX2660 is a microbiota-based in vivo biotherapeutic drug that can deliver a broad-spectrum and diverse microbial collection to the intestines to reduce repeated infections of Clostridium difficile
.
The therapy has been granted Fast Track status, Orphan Drug status and Breakthrough Therapy designation by the FDA
Note: The original text has been deleted
